This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SNNA Sienna Biopharmaceuticals (SNNA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Sienna Biopharmaceuticals Stock (NASDAQ:SNNA) 30 days 90 days 365 days Advanced Chart Get SNNA alerts:Sign Up Key Stats Today's Range$0.11▼$0.1750-Day Range$0.14▼$0.1452-Week Range$0.06▼$3.80Volume13.32 million shsAverage Volume1.87 million shsMarket Capitalization$4.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.Read More… Receive SNNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sienna Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SNNA Stock News Headlines2025 Toyota Sienna Review: A Family Road Trip from Atlanta to OrlandoJune 29 at 11:11 PM | msn.comSienna Miller's beloved basket bag is still available to buy - and it's more affordable than you might thinkJune 27, 2025 | msn.comFine. Don’t believe me. They called me an alarmist... When in 2010 I said America’s debt was out of control. When I warned it would unleash a wave of civil unrest, society collapse, inflation, and currency debasement, they called me crazy. When I said the dollar’s reign was coming to an end… that interest payments would one day overwhelm our budget… they said: that’ll never happen here. And yet – here we are. America’s national debt just blew past $37 trillion.July 1 at 2:00 AM | Porter & Company (Ad)Sienna Toohey eclipses Leisel Jones feat as swimming world rallies around teen after poolside interviewJune 11, 2025 | msn.comWho is Sienna Toohey? Australian teenage swimmer qualifies for senior DolphinsJune 11, 2025 | msn.comTeenager Sienna Toohey shines at the Australian Swimming Trials with 100m breaststroke final winJune 10, 2025 | msn.comVolunteer Sienna, 14, recognised for her efforts helping disabled horse ridersJune 10, 2025 | uk.news.yahoo.comTrinity’s Sienna Chirieleison repeats as Keystone Player of the Year amid Mid-Penn girls lacrosse All-Star picksJune 6, 2025 | msn.comSee More Headlines SNNA Stock Analysis - Frequently Asked Questions How were Sienna Biopharmaceuticals' earnings last quarter? Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) released its earnings results on Thursday, March, 14th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.10. When did Sienna Biopharmaceuticals IPO? Sienna Biopharmaceuticals (SNNA) raised $64 million in an initial public offering on Thursday, July 27th 2017. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO. What other stocks do shareholders of Sienna Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sienna Biopharmaceuticals investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Motif Bio (MTFB) and Ritter Pharmaceuticals (RTTR). Company Calendar Last Earnings3/14/2019Today7/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SNNA CIK1656328 Webwww.siennabio.com Phone(818) 629-2256FaxN/AEmployees39Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-177.36% Return on Assets-52.22% Debt Debt-to-Equity RatioN/A Current Ratio15.27 Quick Ratio15.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book0.11Miscellaneous Outstanding Shares30,908,000Free FloatN/AMarket Cap$4.20 million OptionableNot Optionable Beta2.67 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:SNNA) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sienna Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sienna Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.